The University of Washington’s newest Nobel laureate isn’t letting the prestigious recognition slow down his groundbreaking work in protein design. David Baker, who will receive his share of the 2024 Nobel Prize in Chemistry at a ceremony in Stockholm, remains focused on advancing the rapidly evolving field he helped pioneer.
“The science is incredibly exciting right now,” Baker explained in a recent interview, emphasizing his dedication to pushing research boundaries at the UW Institute for Protein Design, where he serves as director. His commitment to innovation has already resulted in more than 20 spinoff companies, significantly contributing to Seattle’s growing biotechnology sector.
Baker’s research focuses on creating novel proteins through
computational design, essentially engineering molecular machines that can perform specific functions. These designed proteins have wide-ranging applications, from developing new therapeutic treatments to creating sustainable materials. The field has experienced remarkable acceleration thanks to recent advances in artificial intelligence, with tools like RFdiffusion and ProteinMPNN from Baker’s lab, alongside Google’s AlphaFold, making protein design more accessible and efficient than ever before.
The impact of Baker’s work is evident in the commercial success of several institute spinoffs. Notable acquisitions include PvP Biologics, purchased by Takeda Pharmaceuticals for $330 million, and Icosavax, acquired by AstraZeneca in a $1.1 billion deal. The institute has also launched other promising ventures like Cyrus Biotechnology, Sana Biotechnology, A-Alpha Bio, and Xaira
Therapeutics.
Baker’s research has led to significant breakthroughs, including contributions to the world’s first computationally designed
protein-based medicine and a COVID-19 vaccine developed by UW Medicine colleagues. His innovative approach has resulted in over 100 patents, highlighting the practical applications of his theoretical work.
The success of Baker’s lab can be attributed to what he calls the “secret ingredient” – the international talent it attracts. “All the brilliant, super smart, energetic people who come here early in their career from all over the world,” Baker noted, explaining how many of these researchers go on to establish companies in the United States.
Modern AI technologies, similar to those driving popular tools like ChatGPT, are revolutionizing protein engineering. These advances allow for faster prototyping and refinement of designs, accelerating the discovery of proteins capable of specific tasks such as plastic degradation, medical treatments, or industrial process improvements.
Baker, who shares the Nobel Prize with Google DeepMind’s Demis Hassabis and John Jumper for their work in protein structure prediction, sees no slowdown in the field’s momentum. In fact, he anticipates an increase in new company formation, suggesting that the intersection of computational biology and entrepreneurship will continue to expand.
The latest design tools have made the process of engineering biochemical functions more straightforward, though Baker emphasizes that this doesn’t equate to instant drug discovery. Instead, these advances streamline the design process, making it more efficient and accessible to researchers across the field.
As Seattle’s biotech ecosystem continues to grow, Baker’s ongoing work at the Institute for Protein Design remains a crucial driver of innovation and commercial development in the region. His return to the lab after the Nobel recognition signals an unwavering commitment to advancing the science that has already transformed our understanding of protein design and its practical applications.